Alzheimer's disease is more common in elder people , the preliminary analysis shows that the patient is lacking the neurotransmitter acetylcholine (Ach) - which activates muscles found at postsynaptic neuromuscular junctions, especially in muscles and nerves, and helps with short-term memory. acetylcholine esterase is an enzyme that hydrolyses the acetylcholine into acetic acid and choline , decreasing the neurotransmitter acetylcholine concentration in the body so potentially targeting the acetylcholine esterase enzyme leads to improving the patient condition. The current FDA approved drug present are • ZINC597013 (Donepezil) • ZINC4413 (Rivastigmine) • ZINC491073 (Galantamine) • ZINC12504439 (Tacrine(8)-4-Aminoquinoline) • ZINC14946303 (Cellulose Triacetate) acetylcholinesterase inhibitor, donepezil the current FDA-approved drug is useful for the treatment of mild-to-moderate Alzheimer's disease during the early stages. Donepezil is a common drug for the treatment , of Alzheimer's disease mainly low to moderate effects of dementia can be treated with generally 3-5 mg/ Day and is also used for dementia associated with Parkinson's disease. Donepezil is absorbed with significant time but completely from the gut showing a peak in plasma in 3 -4 hr and, with regular dosing after 21-50 days , it has a steady concentration in the blood plasma, approximately 99% present as plasma bounded form metabolic excretion mainly through the urine. But a slight increase in the concentration of donepezil produces significant side effects. , Considering its diversity among several potential enzymes, the ligand should be properly bound to the therapeutic site which is the site at which ligand and protein docking cause the inhibition of that enzyme. Molecular docking , is the best tool for analyzing the binding energy and docking score concerning that particular binding site. Several docking programs like Autodock , GOLD, and Glide are designed to perform ligand-protein Docking and help post-dock scoring and analysis.